Boston Scientific Settles Surgical Mesh Claims for Nearly $189 Million
Today Boston Scientific Corp. agreed to pay $188.7 million to settle claims that the company deceptively marketed its transvaginal surgical mesh implants to consumers. The company has been accused of concealing serious risks related the surgical mesh, including chronic pain, urinary dysfunction and incontinence.
“While Boston Scientific was putting income before the health of people in need of care, women were put in danger,” stated New York Attorney General Letitia. According to Reuters, Boston Scientific stated that the settlement was not “an admission of misconduct or liability, and was in shareholders’ best interest” and that last year the company had put aside money to prepare for a settlement.
Last year J&J was ordered to pay $344 million for deceptively marketing its pelvic mesh and failing to notify doctors and consumers of product risks. In April 2019, FDA ordered Boston Scientific and Coloplast to remove all remaining vaginal mesh products from the U.S. market .
Related Articles
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
“We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry.”
-
AI can support device innovation and surgical training, but it requires data and collaboration.
-
Anthony Fernando, CEO and president of Asensus Surgical, discusses the potential benefits of augmented intelligence in robotic surgery for both patients and physicians.
